S&P 500   2,627.92 (+5.60%)
DOW   22,241.10 (+5.65%)
QQQ   193.42 (+5.48%)
AAPL   254.40 (+5.38%)
FB   162.47 (+5.38%)
MSFT   161.93 (+5.27%)
GOOGL   1,158.14 (+5.99%)
AMZN   1,967.10 (+3.17%)
CGC   14.11 (+6.49%)
NVDA   262.30 (+7.54%)
BABA   195.50 (+4.48%)
MU   44.85 (+8.81%)
GE   7.17 (+6.38%)
TSLA   511.25 (+6.51%)
AMD   46.12 (+8.29%)
T   29.13 (+6.04%)
ACB   0.81 (+0.00%)
F   4.58 (+8.03%)
NFLX   372.38 (+2.94%)
GILD   76.57 (-2.10%)
DIS   98.48 (+4.90%)
S&P 500   2,627.92 (+5.60%)
DOW   22,241.10 (+5.65%)
QQQ   193.42 (+5.48%)
AAPL   254.40 (+5.38%)
FB   162.47 (+5.38%)
MSFT   161.93 (+5.27%)
GOOGL   1,158.14 (+5.99%)
AMZN   1,967.10 (+3.17%)
CGC   14.11 (+6.49%)
NVDA   262.30 (+7.54%)
BABA   195.50 (+4.48%)
MU   44.85 (+8.81%)
GE   7.17 (+6.38%)
TSLA   511.25 (+6.51%)
AMD   46.12 (+8.29%)
T   29.13 (+6.04%)
ACB   0.81 (+0.00%)
F   4.58 (+8.03%)
NFLX   372.38 (+2.94%)
GILD   76.57 (-2.10%)
DIS   98.48 (+4.90%)
S&P 500   2,627.92 (+5.60%)
DOW   22,241.10 (+5.65%)
QQQ   193.42 (+5.48%)
AAPL   254.40 (+5.38%)
FB   162.47 (+5.38%)
MSFT   161.93 (+5.27%)
GOOGL   1,158.14 (+5.99%)
AMZN   1,967.10 (+3.17%)
CGC   14.11 (+6.49%)
NVDA   262.30 (+7.54%)
BABA   195.50 (+4.48%)
MU   44.85 (+8.81%)
GE   7.17 (+6.38%)
TSLA   511.25 (+6.51%)
AMD   46.12 (+8.29%)
T   29.13 (+6.04%)
ACB   0.81 (+0.00%)
F   4.58 (+8.03%)
NFLX   372.38 (+2.94%)
GILD   76.57 (-2.10%)
DIS   98.48 (+4.90%)
S&P 500   2,627.92 (+5.60%)
DOW   22,241.10 (+5.65%)
QQQ   193.42 (+5.48%)
AAPL   254.40 (+5.38%)
FB   162.47 (+5.38%)
MSFT   161.93 (+5.27%)
GOOGL   1,158.14 (+5.99%)
AMZN   1,967.10 (+3.17%)
CGC   14.11 (+6.49%)
NVDA   262.30 (+7.54%)
BABA   195.50 (+4.48%)
MU   44.85 (+8.81%)
GE   7.17 (+6.38%)
TSLA   511.25 (+6.51%)
AMD   46.12 (+8.29%)
T   29.13 (+6.04%)
ACB   0.81 (+0.00%)
F   4.58 (+8.03%)
NFLX   372.38 (+2.94%)
GILD   76.57 (-2.10%)
DIS   98.48 (+4.90%)
Log in

NASDAQ:MNOVMediciNova Stock Price, Forecast & News

$3.13
+0.07 (+2.29 %)
(As of 04/6/2020 12:26 PM ET)
Add
Compare
Today's Range
$3.07
Now: $3.13
$3.28
50-Day Range
$2.90
MA: $4.24
$6.15
52-Week Range
$2.79
Now: $3.13
$13.37
Volume56,834 shs
Average Volume187,207 shs
Market Capitalization$137.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective ß2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Read More
MediciNova logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.71 per share

Profitability

Net Income$-12,940,000.00

Miscellaneous

Employees9
Market Cap$137.59 million
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.


MediciNova (NASDAQ:MNOV) Frequently Asked Questions

How has MediciNova's stock been impacted by COVID-19 (Coronavirus)?

MediciNova's stock was trading at $3.29 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MNOV shares have decreased by 4.9% and is now trading at $3.13. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MediciNova?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MediciNova.

When is MediciNova's next earnings date?

MediciNova is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for MediciNova.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings data on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.04. View MediciNova's earnings history.

What price target have analysts set for MNOV?

1 brokerages have issued 12-month target prices for MediciNova's stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate MediciNova's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 251.4% from the stock's current price. View analysts' price targets for MediciNova.

Has MediciNova been receiving favorable news coverage?

News coverage about MNOV stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MediciNova earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutMediciNova.

Who are some of MediciNova's key competitors?

What other stocks do shareholders of MediciNova own?

Who are MediciNova's key executives?

MediciNova's management team includes the following people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
  • Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
  • Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
  • Ms. Carla Reyes, Chief Financial Officer (Age 47)
  • Mr. John O'Neil CPA, Controller

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $3.13.

How big of a company is MediciNova?

MediciNova has a market capitalization of $137.59 million. The biopharmaceutical company earns $-12,940,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. MediciNova employs 9 workers across the globe. View additional information about MediciNova.

What is MediciNova's official website?

The official website for MediciNova is http://medicinova.com/.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]

This page was last updated on 4/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel